Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001622627-25-000039
Filing Date
2025-11-13
Accepted
2025-11-13 16:08:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9821
  Complete submission text file 0001622627-25-000039.txt   11905
Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709
Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 (919) 636-4530
FENNEC PHARMACEUTICALS INC. (Subject) CIK: 0001211583 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-80470 | Film No.: 251478486
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 15 WELLESLEY STREET WEST SUITE 326 TORONTO Ontario, Canada M4Y 0G7
Business Address 15 WELLESLEY STREET WEST SUITE 326 TORONTO Ontario, Canada M4Y 0G7 4167910300
Rosalind Advisors, Inc. (Filed by) CIK: 0001622627 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1130
Type: SCHEDULE 13G